Chargement en cours...
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Fabry disease (FD) is a progressive multisystemic disorder, treatable with recombinant enzyme replacement therapy (agalsidase). However, recent studies suggest an endogenous inhibition of agalsidase in patients with FD, as reported for other lysosomal storage diseases. To assess the clinical consequ...
Enregistré dans:
| Publié dans: | J Am Soc Nephrol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Nephrology
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4696578/ https://ncbi.nlm.nih.gov/pubmed/25933799 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2014121226 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|